Format

Send to

Choose Destination
Int J Clin Pract. 2017 Jan;71(1). doi: 10.1111/ijcp.12898. Epub 2016 Dec 9.

Improved quality of life in asthma patients under long-term therapy: Assessed by AHQ-Japan.

Author information

1
Department of Respiratory Medicine and Allergology, Kindai University Faculty of Medicine, Osakasayama, Japan.
2
Department of Respiratory Medicine, Osaka City University Graduate School and Faculty of Medicine, Osaka, Japan.
3
Department of Respiratory Medicine, Cellular Transplantation Biology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
4
Department of Medicine, Nissay Hospital, Nippon Life Saiseikai Public Interest Incorporated Foundation, Osaka, Japan.
5
Division of Respiratory Medicine, Kobe University Hospital, Kobe, Japan.
6
Department of Respiratory Medicine, Kyoto University, Kyoto, Japan.
7
Department of Respiratory Medicine, National Hospital Organazation Wakayama Hospital, Wakayama, Japan.
8
Second Department of Internal Medicine, Nara Medical University, Nara, Japan.
9
National Hospital Organization Nanao Hospital, Nanao, Japan.

Abstract

BACKGROUND AND OBJECTIVES:

Assessment of the effects of long-term management on patient quality of life (QOL) would be extremely useful for determining asthma treatment strategies. However, no studies have evaluated QOL over an extended period of time. This study evaluated the changes in QOL, drug management and disease severity in the same asthma patients at an interval of approximately 9 years.

METHODS:

We re-surveyed asthma patients enrolled in a survey conducted in 2004 to evaluate the effects of approximately a decade of treatment on disease severity and QOL assessed by the Japanese Asthma Health Questionnaire (AHQ-JAPAN).

RESULTS:

A total of 2179 patients were enrolled in the study from 93 centres, and 1332 patients were included in the per-protocol analysis. Usage rates of inhaled corticosteroids (ICS) for treatment of stable asthma were over 90% at both time points. The AHQ-JAPAN total score improved significantly from 22.2±19.7 in 2004 to 19.7±19.9 in 2013 (P<.001). Significant improvements were also observed in 5 of 6 subscales of AHQ-JAPAN, with Social Activity constituting the sole exception.

CONCLUSIONS:

Asthma severity declined and QOL assessed by AHQ-JAPAN improved, which is considered as a reflection of improved asthma control at least partly attributable to widespread use of anti-inflammatory drugs as represented by ICS. The study also revealed the presence of those with poor QOL, especially in patients with concomitant respiratory diseases, and an increase in severe persistent asthma cases, warranting further long-term efforts at improving QOL.

TRIAL REGISTRATION NUMBER:

UMIN 000010483.

KEYWORDS:

AHQ-Japan questionnaire; Asthma; anti-inflammatory therapy; inhaled corticosteroid; long-acting beta-adrenergic agent; quality of life

PMID:
27933734
DOI:
10.1111/ijcp.12898
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center